David Risinger
Stock Analyst at Leerink Partners
(4.49)
# 295
Out of 5,139 analysts
176
Total ratings
66.67%
Success rate
14.63%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Maintains: Outperform | $54 → $60 | $55.26 | +8.58% | 5 | Jan 13, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $456 → $525 | $441.36 | +18.95% | 6 | Dec 29, 2025 | |
| ROIV Roivant Sciences | Maintains: Outperform | $29 → $32 | $23.13 | +38.35% | 6 | Dec 15, 2025 | |
| XOMA XOMA Royalty | Maintains: Outperform | $58 → $45 | $26.37 | +70.65% | 1 | Dec 11, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Outperform | $886 → $1,104 | $1,038.40 | +6.32% | 17 | Nov 10, 2025 | |
| IMA ImageneBio | Initiates: Outperform | $30 | $6.53 | +359.42% | 1 | Oct 24, 2025 | |
| HALO Halozyme Therapeutics | Upgrades: Market Perform | $70 | $71.21 | -1.70% | 4 | Oct 14, 2025 | |
| JNJ Johnson & Johnson | Downgrades: Market Perform | $169 → $153 | $218.66 | -30.03% | 4 | May 13, 2025 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $762 → $834 | $733.04 | +13.77% | 9 | Feb 5, 2025 | |
| ABBV AbbVie | Upgrades: Outperform | $206 | $214.35 | -3.90% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $69 | $18.80 | +267.02% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $16.05 | -0.31% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $33.40 | +31.74% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $106 → $153 | $46.59 | +228.40% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $15 → $10 | $20.01 | -50.02% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $47 | $45.68 | +2.89% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $267 → $318 | $330.41 | -3.76% | 4 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $11 | $22.20 | -50.45% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $124.91 | -27.15% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $25.65 | +87.13% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $8.76 | +322.37% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $169.41 | +3.89% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $12.86 | +24.42% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $15.03 | +199.40% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $6.98 | +401.43% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $24.53 | +67.14% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $124.65 | +39.59% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $39.55 | +28.95% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $31.76 | -74.81% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $108.83 | -18.22% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $13.41 | -77.63% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $31.63 | -49.42% | 9 | Apr 2, 2020 |
Bristol-Myers Squibb Company
Jan 13, 2026
Maintains: Outperform
Price Target: $54 → $60
Current: $55.26
Upside: +8.58%
Vertex Pharmaceuticals
Dec 29, 2025
Maintains: Outperform
Price Target: $456 → $525
Current: $441.36
Upside: +18.95%
Roivant Sciences
Dec 15, 2025
Maintains: Outperform
Price Target: $29 → $32
Current: $23.13
Upside: +38.35%
XOMA Royalty
Dec 11, 2025
Maintains: Outperform
Price Target: $58 → $45
Current: $26.37
Upside: +70.65%
Eli Lilly and Company
Nov 10, 2025
Upgrades: Outperform
Price Target: $886 → $1,104
Current: $1,038.40
Upside: +6.32%
ImageneBio
Oct 24, 2025
Initiates: Outperform
Price Target: $30
Current: $6.53
Upside: +359.42%
Halozyme Therapeutics
Oct 14, 2025
Upgrades: Market Perform
Price Target: $70
Current: $71.21
Upside: -1.70%
Johnson & Johnson
May 13, 2025
Downgrades: Market Perform
Price Target: $169 → $153
Current: $218.66
Upside: -30.03%
Regeneron Pharmaceuticals
Feb 5, 2025
Upgrades: Outperform
Price Target: $762 → $834
Current: $733.04
Upside: +13.77%
AbbVie
Nov 22, 2024
Upgrades: Outperform
Price Target: $206
Current: $214.35
Upside: -3.90%
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $18.80
Upside: +267.02%
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $16.05
Upside: -0.31%
Sep 17, 2024
Initiates: Outperform
Price Target: $44
Current: $33.40
Upside: +31.74%
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $46.59
Upside: +228.40%
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $20.01
Upside: -50.02%
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $45.68
Upside: +2.89%
Oct 11, 2023
Upgrades: Outperform
Price Target: $267 → $318
Current: $330.41
Upside: -3.76%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $22.20
Upside: -50.45%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $124.91
Upside: -27.15%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $25.65
Upside: +87.13%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $8.76
Upside: +322.37%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $169.41
Upside: +3.89%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $12.86
Upside: +24.42%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $15.03
Upside: +199.40%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $6.98
Upside: +401.43%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $24.53
Upside: +67.14%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $124.65
Upside: +39.59%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $39.55
Upside: +28.95%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $31.76
Upside: -74.81%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $108.83
Upside: -18.22%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $13.41
Upside: -77.63%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $31.63
Upside: -49.42%